The study, published in the journal Molecular Cancer, demonstrates for the first time that SCLC tumor cells rely on the nonsense-mediated mRNA decay (NMD) pathway to cope with their extremely high mutation burden.
This mechanism enables tumor cells to break down harmful mutated products, thereby ensuring their survival; at the same time, however, it makes them vulnerable to new therapeutic approaches.